The estimated Net Worth of Floyd E Bloom is at least $8.39 Milione dollars as of 16 July 2018. Dr Bloom owns over 20,000 units of Alkermes plc stock worth over $3,398,914 and over the last 13 years he sold ALKS stock worth over $4,990,678.
Sign up
Dr Bloom ALKS stock SEC Form 4 insiders trading
Dr has made over 17 trades of the Alkermes plc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of ALKS stock worth $879,000 on 16 July 2018.
The largest trade he's ever made was selling 30,094 units of Alkermes plc stock on 31 January 2013 worth over $697,278. On average, Dr trades about 10,003 units every 85 days since 2011. As of 16 July 2018 he still owns at least 127,923 units of Alkermes plc stock.
You can see the complete history of Dr Bloom stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Floyd E. Bloom biography
Dr. Floyd E. Bloom is the Founder at Alkermes plc.
How old is Dr Bloom?
Dr Bloom is 83, he's been the Founder of Alkermes plc since . There are 1 older and 21 younger executives at Alkermes plc. The oldest executive at Alkermes plc is Dr. Floyd E. Bloom M.D., 84, who is the Founder.
What's Dr Bloom's mailing address?
Floyd's mailing address filed with the SEC is Connaught House, Burlington Rd, Dublin 4, Ireland.
Insiders trading at Alkermes plc
Over the last 13 years, insiders at Alkermes plc have traded over $407,046,771 worth of Alkermes plc stock and bought 86,119 units worth $2,034,840 . The most active insiders traders include Corp Plc Elan Science Three..., Richard F Pops e James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of $1,083,232. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth $53,512.
What does Alkermes plc do?
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.
What does Alkermes plc's logo look like?
Complete history of Dr Bloom stock trades at Alkermes plc
Alkermes plc executives and stock owners
Alkermes plc executives and other stock owners filed with the SEC include:
-
Richard Pops,
Chairman of the Board, Chief Executive Officer -
Craig Hopkinson,
Executive Vice President, Research and Development and Chief Medical Officer -
David Gaffin,
Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary -
James Frates,
Chief Financial Officer, Senior Vice President -
Michael Landine,
Senior Vice President - Corporate Development, Chief Risk Officer -
Richard F. Pops,
Chairman & CEO -
Dr. Craig C. Hopkinson,
Exec. VP of R&D and Chief Medical Officer -
David Joseph Gaffin,
Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. -
Frank Wilson,
Independent Director -
Richard Gaynor,
Independent Director -
Michael J. Landine,
Sr. VP of Corp. Devel. & Chief Risk Officer -
Paul Mitchell,
Independent Director -
Robert Breyer,
Independent Director -
David Anstice,
Lead Independent Director -
Nancy Snyderman,
Independent Director -
Wendy Dixon,
Independent Director -
Nancy Wysenski,
Independent Director -
Shane Cooke,
Director -
Iain Brown,
Senior Vice President - Finance, Chief Accounting Officer -
Peter Norman,
Sr. VP of Policy & Gov. Relations -
Iain Michael Brown,
Sr. VP & CFO -
Dr. Floyd E. Bloom M.D.,
Founder -
Stephen Schiavo,
Sr. VP of HR -
Eva Stroynowski,
VP of Product & R&D Communications, Public Affairs -
Sandra Coombs,
Co-Head of Investor Relations -
Blair C. Jackson,
Exec. VP & COO -
Dr. Floyd E. Bloom,
Founder -
Floyd E Bloom,
Director -
Elliot Ehrich,
SVP, R&D & CMO, Alkermes, Inc. -
Mark Stejbach,
Chief Commercial Officer -
James A. Jr. Robinson,
President & COO,Alkermes, Inc. -
Nancy Lurker,
Director -
Rebecca Peterson,
SVP, Corporate Communications -
Geraldine Henwood,
Director -
Kathryn L Biberstein,
SVP, GC, Secretary, Alks, Inc. -
Gordon G Pugh,
SVP, COO & CRO, Alkermes, Inc. -
James L Botkin,
SVP, Alkermes Gainesville LLC -
Mark B Skaletsky,
Director -
Corp Plc Elan Science Three...,
-
Christian Todd Nichols,
SVP, Chief Commercial Officer -
Brian P Mckeon,
Director -
David Angelo Jr. Daglio,
Director -
Blair Curtis Jackson,
EVP, Chief Operating Officer -
Emily Peterson Alva,
Director -
Cato T Laurencin,
Director -
Christopher I Wright,
Director -
Samuel Joseph Parisi,
VP, Finance (Interim PAO)